Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.43 Insider Own9.50% Shs Outstand4.05M Perf Week-27.18%
Market Cap8.79M Forward P/E- EPS next Y-1.59 Insider Trans0.00% Shs Float3.67M Perf Month31.52%
Income-7.75M PEG- EPS next Q-0.42 Inst Own6.55% Short Float0.24% Perf Quarter66.76%
Sales0.00M P/S- EPS this Y47.78% Inst Trans- Short Ratio0.00 Perf Half Y-25.68%
Book/sh2.45 P/B0.88 EPS next Y15.16% ROA-144.46% Short Interest0.01M Perf Year-71.74%
Cash/sh0.70 P/C3.11 EPS next 5Y- ROE-208.36% 52W Range0.76 - 14.00 Perf YTD16.67%
Dividend Est.- P/FCF- EPS past 5Y38.36% ROI-189.74% 52W High-84.50% Beta1.25
Dividend TTM- Quick Ratio4.90 Sales past 5Y0.00% Gross Margin- 52W Low183.66% ATR (14)0.44
Dividend Ex-Date- Current Ratio4.90 EPS Y/Y TTM49.74% Oper. Margin0.00% RSI (14)55.67 Volatility27.14% 19.84%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price7.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q57.01% Payout- Rel Volume0.02 Prev Close2.32
Sales Surprise- EPS Surprise7.45% Sales Q/Q- EarningsNov 14 BMO Avg Volume6.36M Price2.17
SMA2028.57% SMA5034.49% SMA200-21.08% Trades Volume152,897 Change-6.47%
Date Action Analyst Rating Change Price Target Change
Oct-30-18Initiated Maxim Group Buy $5
Oct-11-18Initiated Dawson James Buy
Apr-10-24 11:53AM
Apr-02-24 08:30AM
Mar-01-24 07:00PM
Feb-28-24 09:30AM
09:00AM Loading…
Feb-15-24 09:00AM
Feb-13-24 09:15AM
Jan-18-24 08:30AM
Dec-20-23 09:00AM
Nov-29-23 04:05PM
Nov-14-23 05:02PM
Oct-31-23 08:30AM
Oct-30-23 12:00PM
Oct-25-23 08:00AM
Oct-24-23 04:30PM
08:00AM Loading…
Oct-20-23 08:00AM
Oct-19-23 12:00PM
Oct-18-23 08:00AM
Sep-28-23 07:00AM
Sep-05-23 08:30AM
Aug-28-23 08:30AM
Aug-23-23 08:30AM
Aug-21-23 08:30AM
Aug-04-23 08:30AM
Jul-19-23 09:59AM
Jul-11-23 08:30AM
Jun-01-23 09:00AM
May-12-23 08:30AM
08:30AM Loading…
May-10-23 08:30AM
Apr-04-23 09:40AM
Mar-30-23 04:05PM
Mar-21-23 09:00AM
Mar-08-23 09:00AM
Mar-07-23 01:51PM
Mar-06-23 04:19PM
Mar-02-23 09:00AM
Feb-28-23 05:27AM
Feb-27-23 09:00AM
Feb-24-23 07:00AM
Feb-21-23 09:00AM
Feb-01-23 09:00AM
Dec-01-22 09:55AM
Nov-14-22 08:30AM
Oct-19-22 04:57PM
Sep-26-22 12:43PM
Sep-06-22 10:02AM
Sep-01-22 09:55AM
Aug-29-22 07:19AM
Aug-26-22 07:42AM
Aug-22-22 04:30PM
Aug-16-22 09:15AM
Jul-20-22 07:00AM
Jul-18-22 09:25AM
Jun-28-22 11:49AM
Jun-27-22 09:16AM
Jun-14-22 10:48AM
May-19-22 09:25AM
May-16-22 09:25AM
May-05-22 04:05PM
May-04-22 09:15AM
Apr-06-22 07:47AM
Mar-22-22 09:15AM
Feb-24-22 09:15AM
Feb-16-22 09:26AM
Feb-11-22 09:00AM
Feb-09-22 09:25AM
Jan-24-22 09:25AM
Jan-12-22 09:40AM
Jan-10-22 09:03AM
Dec-22-21 09:25AM
Dec-08-21 09:25AM
Nov-29-21 09:00AM
Nov-17-21 09:42AM
Nov-10-21 09:26AM
Nov-09-21 09:15AM
Nov-03-21 09:10AM
Oct-21-21 01:06PM
Oct-18-21 09:30AM
Oct-05-21 09:25AM
Oct-04-21 04:30PM
Sep-30-21 09:25AM
Sep-28-21 09:49AM
Sep-15-21 10:07AM
Sep-13-21 09:30AM
Sep-07-21 09:00AM
Aug-31-21 09:30AM
Aug-20-21 10:45AM
Aug-12-21 02:50PM
Aug-10-21 09:30AM
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuyler KevinDirectorSep 29 '23Buy2.747001,918700Oct 03 08:54 AM